Clinical Trial Services

Oct 20, 2017
By Pharmaceutical Technology Editors
The company has announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support preclinical and clinical programs.
Oct 06, 2017
Pharmaceutical Technology
By Pharmaceutical Technology Editors
Cytel, a biometrics CRO and clinical trial software provider, announced that it will be adding a new location for clinical development in Basel, Switzerland.
Oct 03, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
PCI Pharma Services, a pharmaceutical outsourcing services provider, will acquire Millmount Healthcare, a pharmaceutical and healthcare contract packaging services provider, to expand its European services.
Feb 02, 2016
By Pharmaceutical Technology Editors
Catalent plans a $4.6 million investment to expand secondary packaging and storage in Asia.
Feb 01, 2016
Pharmaceutical Technology
Only half of new drugs make it past Phase III. Adopting best practices and collaborating more closely with contract research organizations can help ensure success.
Feb 01, 2016
Pharmaceutical Technology
Mergers and acquisitions have changed the shape of the contract services market as big players seek to build full-service capabilities.
Feb 01, 2016
Pharmaceutical Technology
Steven Denham, director of biostatistics at MPI Research, discusses the impact the Standard for Exchange of Nonclinical Data may have on the pharmaceutical industry.
Sep 08, 2015
By Pharmaceutical Technology Editors
The partners will collaborate on a project to capture and integrate clinical trial data metrics on investigational cancer medications.
May 26, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
EMA confirms its recommendation to suspend medicines approved based on GVK Biosciences studies.
Apr 15, 2015
By Pharmaceutical Technology Editors
Pfizer announces that its Phase III trial for Ibrance met its primary endpoint and was ended early due to efficacy based on an assessment by an independent Data Monitoring Committee.
native1_300x100
lorem ipsum